Intech Investment Management LLC Has $10.63 Million Stock Position in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)

Intech Investment Management LLC increased its position in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Free Report) by 200.3% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 161,735 shares of the biotechnology company's stock after buying an additional 107,879 shares during the period. Intech Investment Management LLC owned 0.08% of BioMarin Pharmaceutical worth $10,631,000 at the end of the most recent reporting period.

Several other large investors have also modified their holdings of the company. Merit Financial Group LLC acquired a new position in BioMarin Pharmaceutical during the 4th quarter valued at $317,000. Assenagon Asset Management S.A. raised its stake in BioMarin Pharmaceutical by 461.3% during the 4th quarter. Assenagon Asset Management S.A. now owns 611,667 shares of the biotechnology company's stock valued at $40,205,000 after purchasing an additional 502,695 shares during the last quarter. Wedmont Private Capital acquired a new position in BioMarin Pharmaceutical during the 4th quarter valued at $430,000. Swedbank AB raised its stake in BioMarin Pharmaceutical by 11.2% during the 4th quarter. Swedbank AB now owns 432,122 shares of the biotechnology company's stock valued at $28,403,000 after purchasing an additional 43,593 shares during the last quarter. Finally, EULAV Asset Management raised its stake in BioMarin Pharmaceutical by 12.9% during the 3rd quarter. EULAV Asset Management now owns 131,000 shares of the biotechnology company's stock valued at $9,208,000 after purchasing an additional 15,000 shares during the last quarter. 98.71% of the stock is owned by institutional investors.

Remove Ads

Wall Street Analysts Forecast Growth

Several equities analysts recently commented on the stock. UBS Group upped their target price on shares of BioMarin Pharmaceutical from $109.00 to $113.00 and gave the company a "buy" rating in a research note on Thursday, February 20th. StockNews.com upgraded shares of BioMarin Pharmaceutical from a "buy" rating to a "strong-buy" rating in a research note on Tuesday. Scotiabank increased their price objective on shares of BioMarin Pharmaceutical from $78.00 to $80.00 and gave the company a "sector perform" rating in a research note on Thursday, February 20th. Cantor Fitzgerald restated an "overweight" rating and issued a $90.00 price objective on shares of BioMarin Pharmaceutical in a research note on Thursday, February 20th. Finally, Bank of America increased their price objective on shares of BioMarin Pharmaceutical from $99.00 to $103.00 and gave the company a "buy" rating in a research note on Thursday, February 20th. Seven investment analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, BioMarin Pharmaceutical currently has an average rating of "Moderate Buy" and an average target price of $94.00.

BioMarin Pharmaceutical Price Performance

NASDAQ:BMRN traded down $0.36 during mid-day trading on Friday, reaching $71.24. 3,096,683 shares of the company were exchanged, compared to its average volume of 1,784,696. The stock has a market cap of $13.59 billion, a PE ratio of 32.38, a PEG ratio of 0.61 and a beta of 0.33. The company has a quick ratio of 2.62, a current ratio of 5.33 and a debt-to-equity ratio of 0.11. BioMarin Pharmaceutical Inc. has a 12 month low of $60.63 and a 12 month high of $94.85. The company has a fifty day moving average of $66.58 and a 200 day moving average of $68.28.

BioMarin Pharmaceutical (NASDAQ:BMRN - Get Free Report) last issued its earnings results on Wednesday, February 19th. The biotechnology company reported $0.72 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.54 by $0.18. The company had revenue of $747.31 million for the quarter, compared to analyst estimates of $711.05 million. BioMarin Pharmaceutical had a net margin of 14.96% and a return on equity of 9.91%. On average, research analysts anticipate that BioMarin Pharmaceutical Inc. will post 3.15 EPS for the current fiscal year.

Insider Activity at BioMarin Pharmaceutical

In related news, CAO Erin Burkhart sold 1,295 shares of the stock in a transaction that occurred on Wednesday, March 19th. The shares were sold at an average price of $71.52, for a total value of $92,618.40. Following the sale, the chief accounting officer now directly owns 16,955 shares in the company, valued at $1,212,621.60. This trade represents a 7.10 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. 1.85% of the stock is currently owned by corporate insiders.

BioMarin Pharmaceutical Company Profile

BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.